{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:02Z","timestamp":1794047462711,"version":"4.8.0"},"reference-count":43,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"7","license":[{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>B-cell precursor acute lymphoblastic leukemia (BCP-ALL) can hijack the normal bone marrow microenvironment to create a leukemic niche which facilitates blast cell survival and promotes drug resistance. Bone marrow-derived mesenchymal stromal cells (MSC) mimic this protective environment in ex vivo co-cultures with leukemic cells obtained from children with newly diagnosed BCP-ALL. We examined the potential mechanisms of this protection by RNA sequencing of flow-sorted MSC after co-culture with BCP-ALL cells. Leukemic cells induced an interferon (IFN)-related gene signature in MSC, which was partially dependent on direct cell-cell signaling. The signature was selectively induced by BCP-ALL cells, most profoundly by ETV6-RUNX1-positive ALL cells, as co-culture of MSC with healthy immune cells did not provoke a similar IFN signature. Leukemic cells and MSC both secreted IFN\u03b1 and IFN\u03b2, but not IFN\u03b3. In line, the IFN gene signature was sensitive to blockade of IFN\u03b1\/\u03b2 signaling, but less to that of IFN\u03b3. The viability of leukemic cells and level of resistance to three chemotherapeutic agents was not affected by interference with IFN signaling using selective IFN\u03b1\/\u03b2 inhibitors or silencing of IFN-related genes. Taken together, our data suggest that the leukemia-induced expression of IFN\u03b1\/\u03b2-related genes by MSC does not support survival of BCP-ALL cells but may serve a different role in the pathobiology of BCP-ALL.<\/jats:p>","DOI":"10.3324\/haematol.2023.283494","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T03:07:01Z","timestamp":1709176021000},"page":"2073-2084","source":"Crossref","is-referenced-by-count":6,"title":["B-cell precursor acute lymphoblastic leukemia elicits an interferon-\u03b1\/\u03b2 response in bone marrow-derived mesenchymal stroma"],"prefix":"10.3324","volume":"109","author":[{"given":"Mandy W. E.","family":"Smeets","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth M. P.","family":"Steeghs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Orsel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke","family":"Stalpers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrthe M. P.","family":"Vermeeren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina H. J.","family":"Veltman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotte","family":"Slenders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Nierkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesca","family":"Van de Ven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique L.","family":"Den Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,2,29]]},"reference":[{"key":"62928","doi-asserted-by":"crossref","unstructured":"B\u00fcrgler S, Nadal D. Pediatric precursor B acute lymphoblastic leukemia: are T helper cells the missing link in the infectious etiology theory?. Mol Cell Pediatr. 2017; 4(1):6.","DOI":"10.1186\/s40348-017-0072-z"},{"key":"62929","doi-asserted-by":"crossref","unstructured":"Kato M, Manabe A. Treatment and biology of pediatric acute lymphoblastic leukemia. Pediatr Int. 2018; 60(1):4-12.","DOI":"10.1111\/ped.13457"},{"key":"62930","doi-asserted-by":"crossref","unstructured":"Pastorczak A, Domka K, Fidyt K, Martyna P, Firczuk M. Mechanisms of immune evasion in acute lymphoblastic leukemia. Cancers (Basel). 2021; 13(7):1536.","DOI":"10.3390\/cancers13071536"},{"key":"62931","doi-asserted-by":"crossref","unstructured":"Steeghs EMP, Boer JM, Hoogkamer AQ. Copy number alterations in B-cell development genes, drug resistance, and clinical outcome in pediatric B-cell precursor acute lymphoblastic leukemia. Sci Rep. 2019; 9(1):4634.","DOI":"10.1038\/s41598-019-41078-4"},{"key":"62932","doi-asserted-by":"crossref","unstructured":"Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015; 373(16):1541-1552.","DOI":"10.1056\/NEJMra1400972"},{"key":"62933","doi-asserted-by":"crossref","unstructured":"Schwab C, Harrison CJ. Advances in B-cell precursor acute lymphoblastic leukemia genomics. Hemasphere. 2018; 2(4):e53.","DOI":"10.1097\/HS9.0000000000000053"},{"key":"62934","doi-asserted-by":"crossref","unstructured":"Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020; 105(11):2524-2539.","DOI":"10.3324\/haematol.2020.247031"},{"key":"62935","doi-asserted-by":"crossref","unstructured":"Pieters R, De Groot-Kruseman H, Van Der Velden V. Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the Dutch Childhood Oncology Group. J Clin Oncol. 2016; 34(22):2591-2601.","DOI":"10.1200\/JCO.2015.64.6364"},{"key":"62936","doi-asserted-by":"crossref","unstructured":"Naderi EH, Skah S, Ugland H. Bone marrow stroma-derived PGE2 protects BCP-ALL cells from DNA damage-induced p53 accumulation and cell death. Mol Cancer. 2015; 14(1):1-12.","DOI":"10.1186\/s12943-014-0278-9"},{"key":"62937","doi-asserted-by":"crossref","unstructured":"Polak R, De Rooij B, Pieters R, Den Boer ML. B-cell precursor acute lymphoblastic leukemia cells use tunneling nanotubes to orchestrate their microenvironment. Blood. 2015; 126(21):2404-2414.","DOI":"10.1182\/blood-2015-03-634238"},{"key":"62938","doi-asserted-by":"crossref","unstructured":"Usmani S, Sivagnanalingam U, Tkachenko O, Nunez L, Shand JC, Mullen CA. Support of acute lymphoblastic leukemia cells by nonmalignant bone marrow stromal cells. Oncol Lett. 2019; 17(6):5039-5049.","DOI":"10.3892\/ol.2019.10188"},{"key":"62939","doi-asserted-by":"crossref","unstructured":"Duan CW, Shi J, Chen J. Leukemia propagating cells rebuild an evolving niche in response to therapy. Cancer Cell. 2014; 25(6):778-793.","DOI":"10.1016\/j.ccr.2014.04.015"},{"key":"62940","doi-asserted-by":"crossref","unstructured":"Portale F, Cricr\u00ec G, Bresolin S. ActivinA: a new leukemia-promoting factor conferring migratory advantage to B-cell precursor-acute lymphoblastic leukemic cells. Haematologica. 2019; 104(3):533-545.","DOI":"10.3324\/haematol.2018.188664"},{"key":"62941","doi-asserted-by":"crossref","unstructured":"De Rooij B, Polak R, Stalpers F, Pieters R, Den Boer ML. Tunneling nanotubes facilitate autophagosome transfer in the leukemic niche. Leukemia. 2017; 31(7):1651-1654.","DOI":"10.1038\/leu.2017.117"},{"key":"62942","doi-asserted-by":"crossref","unstructured":"Colmone A, Amorim M, Pontier AL, Wang S, Jablonski E, Sipkins DA. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science. 2008; 322(5909):1861-1865.","DOI":"10.1126\/science.1164390"},{"key":"62943","doi-asserted-by":"crossref","unstructured":"Baryawno N, Przybylski D, Kowalczyk MS. A cellular taxonomy of the bone marrow stroma in homeostasis and leukemia. Cell. 2019; 177(7):1915-1932.","DOI":"10.1016\/j.cell.2019.04.040"},{"key":"62944","doi-asserted-by":"crossref","unstructured":"van den Berk LCJ, van der Veer A, Willemse ME. Disturbed CXCR4\/CXCL12 axis in paediatric precursor B-cell acute lymphoblastic leukaemia. Br J Haematol. 2014; 166(2):240-249.","DOI":"10.1111\/bjh.12883"},{"key":"62945","doi-asserted-by":"crossref","unstructured":"Smids C, Horje CSHT, Nierkens S. Candidate serum markers in early Crohn\u2019s disease: predictors of disease course. J Crohns Colitis. 2017; 11(9):1090-1100.","DOI":"10.1093\/ecco-jcc\/jjx049"},{"key":"62946","doi-asserted-by":"crossref","unstructured":"van Iersel MP, Kelder T, Pico AR. Presenting and exploring biological pathways with PathVisio. BMC Bioinformatics. 2008; 9:399.","DOI":"10.1186\/1471-2105-9-399"},{"key":"62947","doi-asserted-by":"crossref","unstructured":"Zaliova M, Stuchly J, Winkowska L. Genomic landscape of pediatric B-other acute lymphoblastic leukemia in a consecutive European cohort. Haematologica. 2019; 104(7):1396-1406.","DOI":"10.3324\/haematol.2018.204974"},{"key":"62948","doi-asserted-by":"crossref","unstructured":"Pastorczak A, Domka K, Fidyt K, Martyna P, Firczuk M. Mechanisms of immune evasion in acute lymphoblastic leukemia. Cancers (Basel). 2021; 13(7):1536.","DOI":"10.3390\/cancers13071536"},{"key":"62949","doi-asserted-by":"crossref","unstructured":"Mostafavi S, Yoshida H, Moodley D. Parsing the interferon transcriptional network and its disease associations. Cell. 2016; 164(3):564-578.","DOI":"10.1016\/j.cell.2015.12.032"},{"key":"62950","doi-asserted-by":"crossref","unstructured":"Einav U, Tabach Y, Getz G. Gene expression analysis reveals a strong signature of an interferon-induced pathway in childhood lymphoblastic leukemia as well as in breast and ovarian cancer. Oncogene. 2005; 24(42):6367-6375.","DOI":"10.1038\/sj.onc.1208797"},{"key":"62951","doi-asserted-by":"crossref","unstructured":"Dander E, Palmi C, D\u2019Amico G, Cazzaniga G. The bone marrow niche in B-cell acute lymphoblastic leukemia: the role of microenvironment from pre-leukemia to overt leukemia. Int J Mol Sci. 2021; 22(9):4426.","DOI":"10.3390\/ijms22094426"},{"key":"62952","doi-asserted-by":"crossref","unstructured":"Schreiber G. The molecular basis for differential type I interferon signaling. J Biol Chem. 2017; 292(18):7285-7294.","DOI":"10.1074\/jbc.R116.774562"},{"key":"62953","doi-asserted-by":"crossref","unstructured":"Boukhaled GM, Harding S, Brooks DG. Opposing roles of type I interferons in cancer immunity. Annu Rev Pathol. 2021; 16:167-198.","DOI":"10.1146\/annurev-pathol-031920-093932"},{"key":"62954","doi-asserted-by":"crossref","unstructured":"Chmiest D, Sharma N, Zanin N. Spatiotemporal control of interferon-induced JAK\/STAT signalling and gene transcription by the retromer complex. Nat Commun. 2016; 7:13476.","DOI":"10.1038\/ncomms13476"},{"key":"62955","doi-asserted-by":"crossref","unstructured":"Zanin N, Viaris de Lesegno C, Lamaze C, Blouin CM. Interferon receptor trafficking and signaling: journey to the cross roads. Front Immunol. 2021; 11:615603.","DOI":"10.3389\/fimmu.2020.615603"},{"key":"62956","doi-asserted-by":"crossref","unstructured":"Adie EJ, Francis MJ, Davies J. CypHer 5: a generic approach for measuring the activation and trafficking of G protein-coupled receptors in live cells. Assay Drug Dev Technol. 2003; 1(2):251-259.","DOI":"10.1089\/15406580360545062"},{"key":"62957","doi-asserted-by":"crossref","unstructured":"Nath N, Godat B, Zimprich C. Homogeneous plate based antibody internalization assay using pH sensor fluorescent dye. J Immunol Methods. 2016; 431:11-21.","DOI":"10.1016\/j.jim.2016.02.001"},{"key":"62958","doi-asserted-by":"crossref","unstructured":"Budhwani M, Mazzieri R, Dolcetti R. Plasticity of type I interferon-mediated responses in cancer therapy: from antitumor immunity to resistance. Front Oncol. 2018; 8:322.","DOI":"10.3389\/fonc.2018.00322"},{"key":"62959","doi-asserted-by":"crossref","unstructured":"Provance OK, Lewis-Wambi J. Deciphering the role of interferon alpha signaling and microenvironment crosstalk in inflammatory breast cancer. Breast Cancer Res. 2019; 21(1):59.","DOI":"10.1186\/s13058-019-1140-1"},{"key":"62960","doi-asserted-by":"crossref","unstructured":"Cheon H, Borden EC, Stark GR. Interferons and their stimulated genes in the tumor microenvironment. Semin Oncol. 2014; 41(2):156-173.","DOI":"10.1053\/j.seminoncol.2014.02.002"},{"key":"62961","doi-asserted-by":"crossref","unstructured":"Weichselbaum RR, Ishwaran H, Yoon T. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci U S A. 2008; 105(47):18490-18495.","DOI":"10.1073\/pnas.0809242105"},{"key":"62962","doi-asserted-by":"crossref","unstructured":"Duarte CW, Willey CD, Zhi D. Expression signature of IFN\/STAT1 signaling genes predicts poor survival outcome in glioblastoma multiforme in a subtype-specific manner. PLoS One. 2012; 7(1):e29653.","DOI":"10.1371\/journal.pone.0029653"},{"key":"62963","doi-asserted-by":"crossref","unstructured":"Erdal E, Haider S, Rehwinkel J, Harris AL, McHugh PJ. A prosurvival DNA damage-induced cytoplasmic interferon response is mediated by end resection factors and is limited by Trex1. Genes Dev. 2017; 31(4):353-369.","DOI":"10.1101\/gad.289769.116"},{"key":"62964","doi-asserted-by":"crossref","unstructured":"Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le Bon A, Melero I. Direct effects of type I interferons on cells of the immune system. Clin Cancer Res. 2011; 17(9):2619-2627.","DOI":"10.1158\/1078-0432.CCR-10-1114"},{"key":"62965","doi-asserted-by":"crossref","unstructured":"Lee AJ, Ashkar AA. The dual nature of type I and type II interferons. Front Immunol. 2018; 9:2061.","DOI":"10.3389\/fimmu.2018.02061"},{"key":"62966","doi-asserted-by":"crossref","unstructured":"Wennerberg E, Pfefferle A, Ekblad L. Human anaplastic thyroid carcinoma cells are sensitive to NK cell-mediated lysis via ULBP2\/5\/6 and chemoattract NK cells. Clin Cancer Res. 2014; 20(22):5733-5744.","DOI":"10.1158\/1078-0432.CCR-14-0291"},{"key":"62967","doi-asserted-by":"crossref","unstructured":"Gun SY, Lee SWL, Sieow JL, Wong SC. Targeting immune cells for cancer therapy. Redox Biol. 2019; 25:101174.","DOI":"10.1016\/j.redox.2019.101174"},{"key":"62968","doi-asserted-by":"crossref","unstructured":"Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol. 2015; 15(7):405-414.","DOI":"10.1038\/nri3845"},{"key":"62969","doi-asserted-by":"crossref","unstructured":"Kumar A, Taghi Khani A, Duault C. Intrinsic suppression of type I interferon production underlies the therapeutic efficacy of IL-15-producing natural killer cells in B-cell acute lymphoblastic leukemia. J Immunother Cancer. 2023; 11(5):e006649.","DOI":"10.1136\/jitc-2022-006649"},{"key":"62970","doi-asserted-by":"crossref","unstructured":"Magenau JM, Peltier D, Riwes M. Type 1 interferon to prevent leukemia relapse after allogeneic transplantation. Blood Adv. 2021; 5(23):5047-5056.","DOI":"10.1182\/bloodadvances.2021004908"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283494\/76724","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283494\/77158","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11478\/76724","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:53Z","timestamp":1794045953000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":43,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283494","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,29]]}}}